Skip to content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Get the latest shareable resources on coping with COVID-19 from NIMH: https://www.nimh.nih.gov/covid19

Understanding How Ketamine Affects Brain Chemistry

Join a Research Study: Enrolling nationally from around the country

To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010].

The purpose of this study is to evaluate how a dose of ketamine affects brain chemistry, and how it alleviates depression symptoms so quickly. Ketamine is a general anesthetic medication used to put people to sleep for surgery.

This inpatient study is enrolling eligible healthy adults, ages 18 to 65, who are free of psychiatric illness and serious medical conditions. The study lasts up to 5 days, and procedures include a ketamine infusion, psychological testing, sleep studies, an optional lumbar puncture, and optional brain scans.

The study is conducted at the NIH Clinical Center in Bethesda, MD. There is no cost to participate and compensation is provided. This study enrolls eligible participants locally from within 50 miles of the NIH Clinical Center in Bethesda, Maryland. Travel arrangements are provided, and costs are covered by NIMH (arrangements vary by distance).

First steps to participate include, calling NIMH, learning study details, asking about your eligibility, and consenting to participate.